Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...
Cellares’ Cell Shuttle performed all unit operations in an automated manner, including cell isolation, enrichment, gene ...
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), has concluded the Technology Adoption ...
The Technology Adoption Program successfully tested the ability of the Bridgewater Smart Factory to automate, lower costs and ...
pathway in patients with systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid arthritis (RA) and systemic scleroderma (SSc) and to evaluate the potential to develop ...
Data from 237 consecutive control patients with a scleroderma-like disorder (eosinophilic fasciitis (also called Shulman's disease or diffuse fasciitis with eosinophilia), scleromyxedema, systemic ...
Delayed esophageal transit on scintigraphy among patients with SSc is linked to a more severe disease phenotype.
Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients ...
GB News on MSN6d
From bedwetting to writer's cramp, the success rate of EVERY benefit claim EXPOSED as Labour wields axeFrom wetting the bed to acne, we have crunched the numbers on the success rate of every single disability claim. It comes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback